Literature DB >> 22301703

Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

Eleftherios P Samartzis1, Nicolas Samartzis, Aurelia Noske, André Fedier, Rosmarie Caduff, Konstantin J Dedes, Daniel Fink, Patrick Imesch.   

Abstract

Mutations of the tumor-suppressor gene ARID1A result in the loss of protein expression of the BRG-associated factor 250a (BAF250a), a large subunit of transcription-regulating Human SWI/SNF complexes, which have an important role in the control of cell proliferation and tumor suppression. ARID1A mutations are particularly frequent in endometriosis-associated ovarian clear cell and endometrioid carcinomas, and were recently described as a possible key mechanism and early step in the transformation of endometriosis into cancer. Here, we examined the immunohistochemical expression pattern of BAF250a in a tissue microarray including 74 endometriosis and 30 endometrium samples. Ovarian cancer samples (n=136) served as a control. Epithelial BAF250a expression was assessable in 90/104 (87%) and stromal BAF250a expression in 95/104 (91%) of the endometriosis, and endometrium cases due to lack of adequate tissue in some spots. Complete lack of BAF250a expression was observed in three endometriomas (n=3/20, 15%) and one deep-infiltrating endometriosis sample (n=1/22, 5%), but in none of the peritoneal endometriosis (n=0/16) and eutopic endometrium samples (n=0/30). A comparison of the mean immunoreactivity scores revealed a significantly lower expression rate of BAF250a in endometriomas compared with normal endometrium (P<0.0005), as well as peritoneal (P=0.003) and deep-infiltrating endometriosis (P=0.02). Our data demonstrates that a complete loss of BAF250a expression is observable in some endometriotic lesions, especially in endometriomas. In addition, we report that a partial loss of BAF250a expression is occurring in the form of cell clusters indicating a clonal loss of BAF250a expression in these cells. The loss of expression of the tumor-suppressor protein BAF250a in some endometriomas possibly indicates a risk of malignant transformation in these cases, which could be of importance in the determination of individual treatment strategies. However, its role and value as a prognostic parameter in endometriosis needs to be further studied.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301703     DOI: 10.1038/modpathol.2011.217

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  37 in total

Review 1.  Endometriosis: where are we and where are we going?

Authors:  Alexis D Greene; Stephanie A Lang; Jessica A Kendziorski; Julie M Sroga-Rios; Thomas J Herzog; Katherine A Burns
Journal:  Reproduction       Date:  2016-05-10       Impact factor: 3.906

2.  Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.

Authors:  Song-Zhu Yang; An-Qiang Wang; Juan Du; Jian-Tao Wang; Wei-Wei Yu; Qing Liu; Yan-Fang Wu; Shu-Guang Chen
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  SWI/SNF inactivation in the endometrial epithelium leads to loss of epithelial integrity.

Authors:  Jake J Reske; Mike R Wilson; Jeanne Holladay; Marc Wegener; Marie Adams; Ronald L Chandler
Journal:  Hum Mol Genet       Date:  2020-12-18       Impact factor: 6.150

4.  Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Nao Oumi; Tetsuro Oishi; Tadahiro Shoji; Hiroyuki Fujiwara; Toru Sugiyama; Mitsuaki Suzuki; Junzo Kigawa; Tasuku Harada
Journal:  Int J Clin Oncol       Date:  2015-03-06       Impact factor: 3.402

5.  Cancer-Associated Mutations in Endometriosis without Cancer.

Authors:  Michael S Anglesio; Nickolas Papadopoulos; Ayse Ayhan; Tayyebeh M Nazeran; Michaël Noë; Hugo M Horlings; Amy Lum; Siân Jones; Janine Senz; Tamer Seckin; Julie Ho; Ren-Chin Wu; Vivian Lac; Hiroshi Ogawa; Basile Tessier-Cloutier; Rami Alhassan; Amy Wang; Yuxuan Wang; Joshua D Cohen; Fontayne Wong; Adnan Hasanovic; Natasha Orr; Ming Zhang; Maria Popoli; Wyatt McMahon; Laura D Wood; Austin Mattox; Catherine Allaire; James Segars; Christina Williams; Cristian Tomasetti; Niki Boyd; Kenneth W Kinzler; C Blake Gilks; Luis Diaz; Tian-Li Wang; Bert Vogelstein; Paul J Yong; David G Huntsman; Ie-Ming Shih
Journal:  N Engl J Med       Date:  2017-05-11       Impact factor: 91.245

6.  Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Authors:  Wenbin Xiao; Amad Awadallah; Wei Xin
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

7.  Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.

Authors:  Ayse Ayhan; Tsui-Lien Mao; Tamer Seckin; Chen-Hsuan Wu; Bin Guan; Hiroshi Ogawa; Masayuki Futagami; Hiroki Mizukami; Yoshihito Yokoyama; Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Cancer       Date:  2012-10       Impact factor: 3.437

8.  Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer.

Authors:  Jun Zou; Wan Qin; Lin Yang; Lulu Wang; Yu Wang; Jianfeng Shen; Wei Xiong; Shiying Yu; Shumei Song; Jaffer A Ajani; Shiaw-Yih Lin; Gordon B Mills; Xianglin Yuan; Jianying Chen; Guang Peng
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

9.  Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer.

Authors:  Swati Suryawanshi; Xin Huang; Esther Elishaev; Raluca A Budiu; Lixin Zhang; SungHwan Kim; Nicole Donnellan; Gina Mantia-Smaldone; Tianzhou Ma; George Tseng; Ted Lee; Suketu Mansuria; Robert P Edwards; Anda M Vlad
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

10.  Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Authors:  Masafumi Kato; Masashi Takano; Morikazu Miyamoto; Naoki Sasaki; Tomoko Goto; Ayako Suzuki; Junko Hirata; Hidenori Sasa; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.